Loading...
Intra-arterial Bevacizumab for Posterior Fossa Hemangioblastoma
Sokol, Zachary Hoeft, Ava Kung, David Belman, Neil Oselkin, Martin
Sokol, Zachary
Hoeft, Ava
Kung, David
Belman, Neil
Oselkin, Martin
Citations
Altmetric:
Genre
Journal article
Date
2022-12-17
Advisor
Committee member
Group
Department
Medicine
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.7759/cureus.32624
Abstract
Hemangioblastoma (HB) is a rare, highly vascularized, and benign central nervous system (CNS) tumor. This vascularity is due to a high degree of signaling by vascular endothelial growth factor (VEGF). Consequently, anti-VEGF agents, such as bevacizumab, have been postulated and shown in a few cases to be effective in treating these tumors when surgical therapy is not feasible. Additionally, selective intra-arterial (IA) administration of bevacizumab has shown promise in treating other cancers such as glioblastoma (GBM). Here, we present the case of a 60-year-old female with a symptomatic posterior fossa HB where embolization and surgery were not feasible due to tumor location. She underwent selective IA treatment with bevacizumab, which led to tumor stability and symptomatic improvement. Bevacizumab has been used intravenously (IV) as a treatment for HB, however, its efficacy has not been well-established. This case demonstrates the potential viability of selective bevacizumab in HB, as demonstrated by symptomatic improvement and decreased tumor size on MRI. Further research is needed to demonstrate the specific efficacy of IA bevacizumab for CNS HB when surgery or other treatment modalities are not viable options.
Description
Citation
Sokol Z, Hoeft A, Kung D, et al. (December 17, 2022) Intra-arterial Bevacizumab for Posterior Fossa Hemangioblastoma. Cureus 14(12): e32624. doi:10.7759/cureus.32624
Citation to related work
Springer
Has part
Cureus: Journal of Medical Science, Vol. 14
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu